Koruk et al. in 2004 showed that serum levels of malondialdehyde (MDA), GSH, and SOD were higher in NASH patients than in the control group, suggesting that the antioxidant system has a key role in NAFLD pathogenesis and disease progression [86]. This evidence concerns the gene SOD1 and metabolic dysfunction-associated steatotic liver disease.